secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2025-05-29T23:59:59+00:00
Accession:  0001641172-25-012791
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Cocrystal Pharma Reports CC-42344 Shows 1,000-fold Greater Potency Than Tamiflu Against H5N1 Avian Flu
--------------------------------------------------------------------------------

- CC-42344 exhibited EC50 of 0.003 µM against the 2024 Texas H5N1 strain, ~1,000-fold more potent than Tamiflu (EC50 2.69 µM).
- The PB2 inhibitor targets a highly conserved active site and has shown favorable safety in a Phase 1 study.
- H5N1 has spread in U.S. dairy cattle since March 2024, with rare human cases and low population immunity according to CDC.
- Cocrystal plans further clinical evaluation of CC-42344 for pandemic and seasonal influenza treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225012791/0001641172-25-012791-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225012791/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-012791

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer